Among platforms used in determining the presence of biological markers in surgical pathology specimens, immunohistochemistry is perhaps the most commonly available tool in the routine diagnostic laboratory (2, 3). Immunohistochemistry allows detection of antigens expressed on tumor cells, hence permitting characterization of the tumor. Less commonly used methods in the context of in GU cancers are conventional karyotyping, fluorescent in situ hybridization, and molecular cytogenetics. More novel molecular analyses such as expression profiling, comparative genomic hybridization, single nucleotide polymorphism array, methylation status, and mutational analysis are currently being used to identify specific molecular pathways involved in various GU tumor types, and to identify predictive markers that can provide information on whether there will be response or resistance of cancer to specific types of therapy (4). While new oncologic options are rapidly becoming available for patients with in GU cancers, especially in the metastatic setting, use of predictive biomarkers for clinical stratification and management planning has not yet fully entered routine practice and still await further validation studies (2, 3). contributed equally to this study. Genitourinary (GU) cancers are considered as a challenge field of uro-oncology. In the early phases, GU tumors can be successfully cured by medical, surgical, and radiotherapeutic approaches. Such tumors can progress to an advanced phase. When metastatic, traditional systemic therapies, the main options for treatment, generally have a limited or palliative effect (1).
cancer's molecular profiles following a morphological diagnosis of GU tumors. Great advances have been made in molecular biology analysis techniques, such as next-generation sequencing and whole exome sequencing. The rise of such novel technologies has deeply increased our knowledge on cancer cell biology and development, thus allowing identification of complex genomic alterations. Such findings have then paved the way to healthcare from an individual perspective (2, 3) .
An emerging strategy to individualize therapeutic interventions is based on stem cells. Because of their unique features, they are among the most promising candidates as potential vectors carrying suicide genes into different types of tumors, including GU cancers (2, 3) .
Another emerging strategy, when dealing with prostate for instance, is based on prostate-specific membrane antigen (PSMA), a unique membrane-bound glycoprotein with internalization functions. This is overexpressed manifold on prostate cancer. PSMA can serve as target for delivering therapeutic agents, such as cytotoxins or radionuclides (5) .
"Strategies have also been designed to get over the ability of the neoplastic cells to suppress the immune surveillance that would otherwise protect the host from tumor growth and progression," that is, immunotherapy (1, (6) (7) (8) (9) .
Urothelial carcinoma (UC)
Several molecular and genetic studies have provided a sound basis for the classification of urothelial tumors. Very recent and important developments have been made such as (10):
• The identification of mutations in the fibroblast growth factor receptor 3 gene (FGFR3). This is seen in more than 50% of the urothelial carcinomas (UCs). • The discovery of cDNA profiles in different subsets of cancer. This gives further support to a differentiated taxonomy of UC. • Recent developments and findings in the field of molecular mutational pathway analyses based on next-generation sequencing technology.
All such developments have led to changes that are behind the use of nontraditional approaches to the treatment of UC patients and are ready to modify our daily practice in urooncology. The close correlation between some molecular discoveries and clinical behavior and the identification of their targets at cellular level might benefit their combined use with morphological data for the development of new clinical and biological strategies important to clinical work-up of UC patients (10) . There is wealth of data available to support personalized therapies in UC, based on an integrated approach, including pathological and clinical features as well as molecular biology findings (10) .
Prostate cancer (PCa)
The majority of prostate cancers (PCas) are acinar adenocarcinomas and rely on androgen-dependent signaling for their development and growth. Androgen deprivation therapy is a mainstay in treatment regimens. Recent progress in the definition of the genetic landscape of PCa has shown that genetic heterogeneity surpasses what can be seen morphologically and has the ability to redefine treatments. TMPRSS2-ETS family fusion proteins are unique to PCa, with great role in diagnosis, prognosis, and the development of TMPRSS2-ETS family gene fusion targeted therapy. Inactivation of the tumor suppressor PTEN leads to activation of the PI3K/Akt/mTOR pathway, with prognostic and treatment implications (11) .
Molecular genetic analysis has recently shown that clinically aggressive high-grade neuroendocrine PCa is characterized by overexpression of Aurora A kinase and N-myc genes. Aurora A kinase and N-myc have a pivotal role in the development of the neuroendocrine phenotype and in the discovery of targeted inhibitors for this PCa variant (11) .
Lastly, emerging genetic subtypes, defined by CHD1 inactivation, SPINK1 overexpression, or SPOP mutations, could be all considered potentially important as molecular determinants for personalized treatments (11) .
Renal cell carcinoma (RCC)
Renal cell carcinoma (RCC) is a heterogeneous group of tumors with different histologic subtypes. The majority of adults renal tumors are clear cell RCCs (ccRCCs), characterized by von Hippel-Lindau (VHL) gene changes. Recent advances in the genetic landscape of RCC have demonstrated the genetic heterogeneity of ccRCC as well as the presence of additional ccRCC tumor suppressor genes on chromosome 3p. Due to inactivation of VHL, cancer cells produce the HIF-responsive growth factor VEGF. In a subset of ccRCCs, there is a selective advantage originating from a cooperating mutation that leads to dysregulation of the PI3K--mTORC1 signaling axis. This also represents a potential target for treatment (12) .
The identification of critical biological targets in ccRCC, that is, the VHL and mTORC1 pathways, has resulted in new categories of therapy, including tyrosine kinase inhibitors, monoclonal antibodies, and mTOR inhibitors. All aim at suppressing angiogenesismediated by vascular endothelial growth factor (VEGF) 1. Various VEGF-inhibitors are approved for the treatment of ccRCC. This has recently led to great advancements in the treatment of metastatic ccRCC (12) .
Other gene alterations have been discovered in hereditary cancer syndromes, for example, PTEN, MET, TSC1, TSC2, TFE3, TFEB, MITF, FLCN FH, SDHB, and SDHD. Such genes have a pivotal role in RCC development, prognosis, and targeted therapy (12) .
The associations between histological features and molecular genetics in RCC provide insight into the basis for personalized therapy (12) .
Conclusions: precision medicine
Recent insights and emerging strategies for individualized therapeutic approaches are based on patient's genomic and cancer's molecular profiles. This depends on the significant advances made in molecular biology technologies, such as nextgeneration sequencing and whole-exome sequencing (13) .
The rise of such novel techniques has grayly increased our knowledge on cancer cell biology and development, thus allowing to identify complex abnormalities at the genomic level. These findings have paved the way toward what is called precision medicine, thus providing healthcare from an individual perspective in patients with GU cancers (6) (7) (8) (9) 14) .
